Abstract

The main objective of this study was to determine the place and role of neutron radiation therapy in the treatment of patients with recurrent high-grade glioma. Material and Methods. Treatment outcomes were analyzed in 40 patients who were treated at Oncology Center (Chelyabinsk) and Center for Neutron Therapy (Snezhinsk) from 2005 to 2015. The median age of patients was 45 years. The male to female ratio was 1:1. Recurrent glioblastoma was diagnosed in 19 patients, and anaplastic astrocytoma was revealed in 21 patients. Twenty patients underwent neutron therapy alone,and 20 patients underwent combined neutronphoton radiation therapy. The median overall survival time for all patients with recurrent high-grade glioma was 50 months. The 1-year, 2-year and 3-year survival rates were 94.1 %, 77.8 % and 66.7 % respectively. Results. The median survival time after treatment for relapse was 27 months. The main prognostic factors affecting the treatment outcomes were the age of the patients, histological verification and time to relapse. The method-specific overall survival rate was significantly higher in patients who underwent combined neutron-photon radiation therapy than in patients who underwent neutron therapy alone (48 months versus 20 months, p=0.05).

Highlights

  • Целью исследования явилось определение места и роли нейтронной лучевой терапии в лечении пациентов с рецидивами высокозлокачественных глиом головного мозга

  • Treatment outcomes were analyzed in 40 patients who were treated at Oncology Center (Chelyabinsk) and Center for Neutron Therapy (Snezhinsk) from 2005 to 2015

  • Recurrent glioblastoma was diagnosed in 19 patients, and anaplastic astrocytoma was revealed in 21 patients

Read more

Summary

Anaplastic astrocytoma

Выживаемость после повторного лечения/ Survival after repeated radiation 24 мес/months. Результаты и обсуждение Медиана ОВ для всех пациентов с рецидивами злокачественных глиомам после проведенного лечения составила 50 мес, показатели 1-летней ОВ – 94,1 %; 2-летней – 77,8 %; 3-летней – 66,7 % В рамках проведенного исследования мы оценили воздействие срока наступления рецидива после проведенного лечения на показатели общей выживаемости, ретроспективно разделив всех пациентов на 2 подгруппы: в первую вошел 21 пациент, кому диагноз продолженного роста установлен в срок до 1 года; вторую подгруппу составили 19 пациентов у которых возник рецидив через 12 и более мес. Shiba H., Takeuchi K., Hiramatsu R., Furuse M., Nonoguchi N., Kawabata S., Kuroiwa T., Kondo N., Sakurai Y., Suzuki M., Ono K., Oue S., Ishikawa E., Michiue H., Miyatake S.I. Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas A Pilot Study.

ВКЛАД АВТОРОВ
AUTHOR CONTRIBUTION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call